Indiana Doc Ghosts DEA, Loses Rights to Prescribe Controlled Drugs
Published Date: 1/15/2026
Notice
Summary
Dr. Walter Walters from Indiana lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. Despite multiple attempts, he didn’t respond or ask for a hearing, so the DEA officially revoked his certificate. This means he can’t prescribe or manage controlled drugs anymore, effective immediately, impacting his medical practice and patients.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
DEA Registration Revoked for Indiana Physician
The DEA revoked Certificate of Registration No. FW6683331 issued to Walter Walters, M.D., because he is not authorized to handle controlled substances in Indiana. The Order also denies any pending applications to renew, modify, or add a DEA registration for Dr. Walters in Indiana. The revocation and denials are effective February 17, 2026.
Short Window to Seek Reconsideration
The Order states that the registrant may dispute the Agency's finding by filing a properly supported motion for reconsideration of findings of fact within fifteen calendar days of the date of this Order. Any such motion and response must be filed and served by email to the other party and to the DEA Office of the Administrator.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2026-00625, South Central Florida Express, Inc.-Trackage Rights Exemption-Florida East Coast Railway, LLC
South Central Florida Express (SCFE) is renewing and updating its rights to use tracks owned by Florida East Coast Railway (FECR) in Florida. These rights let SCFE run trains on specific parts of the line between Ft. Pierce and Lake Harbor, including adding new customers. SCFE missed getting official approval back in 2016 but fixed that now, so everything’s official and good to go without extra costs or delays.
Next: 2026-00627, Jason Vanshaar, M.D.; Decision and Order
Dr. Jason Vanshaar from Utah had his DEA license suspended and is facing revocation because he prescribed lots of strong drugs in unsafe ways, risking public health. This affects him directly and means he can’t legally prescribe controlled substances anymore. The decision is final as of early 2026, stopping him from getting new DEA registrations and protecting patients from harm.